# Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients

> **NCT01119937** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 211 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** NVA237
- **DRUG:** Tiotropium

## Key facts

- **NCT ID:** NCT01119937
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-11
- **Final completion:** —
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2013-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01119937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01119937, "Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01119937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*